MOLN — Molecular Partners AG Share Price
0.000.00%
Last trade - 00:00- CH₣127.96m
- -CH₣19.04m
- CH₣4.97m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.9 | ||
| Price to Tang. Book | 0.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 25.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.43% | ||
| Return on Equity | -33.98% | ||
| Operating Margin | -1231.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 9.34 | 9.75 | 189.6 | 7.04 | 4.97 | 1 | 9.67 | -24.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Directors
- William Burns NEC (73)
- Patrick Amstutz CEO (46)
- Andreas Emmenegger CFO (55)
- Michael Stumpp COO (49)
- Nicolas Leupin MGB (48)
- Gwendolyn Fyfe NED (69)
- Steven Holtzman NED (67)
- Sandip Kapadia NED (51)
- Vito Palombella NED (59)
- Michael Vasconcelles NED (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 23rd, 2004
- Public Since
- October 22nd, 2014
- No. of Employees
- 159
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 36,874,641
- Address
- Wagistrasse 14, SCHLIEREN, 8952
- Web
- https://www.molecularpartners.com/
- Phone
- +41 447557700
- Contact
- Seth Lewis
- Auditors
- KPMG AG
Upcoming Events for MOLN
Half Year 2025 Molecular Partners AG Earnings Release
Similar to MOLN
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
FAQ
What is the Molecular Partners AG share price?
As of Today at 22:06 UTC, shares in Molecular Partners AG are trading at CH₣3.47. This share price information is delayed by 15 minutes.
How has the Molecular Partners AG share price performed this year?
Shares in Molecular Partners AG last closed at CH₣3.47 and the price had moved by +6.88% over the past 365 days. In terms of relative price strength the Molecular Partners AG share price has outperformed the FTSE Global All Cap Index by +4.2% over the past year.
What are the analyst and broker recommendations for Molecular Partners AG?
The overall consensus recommendation for Molecular Partners AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Molecular Partners AG dividend yield?
Molecular Partners AG does not currently pay a dividend.
Does Molecular Partners AG pay a dividend?
Molecular Partners AG does not currently pay a dividend.
When does Molecular Partners AG next pay dividends?
Molecular Partners AG does not currently pay a dividend.
How do I buy Molecular Partners AG shares?
To buy shares in Molecular Partners AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Molecular Partners AG?
As of the previous close price of CH₣3.47, shares in Molecular Partners AG had a market capitalisation of CH₣127.96m.
Where are Molecular Partners AG shares listed?
Here are the trading details for Molecular Partners AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: MOLN
What kind of share is Molecular Partners AG?
Based on an overall assessment of its quality, value and momentum Molecular Partners AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Molecular Partners AG share price forecast for 2025?
The analyst consensus target price for shares in Molecular Partners AG is CH₣10.50. That is 202.59% above the last closing price of CH₣3.47.
Analysts covering Molecular Partners AG currently have a consensus Earnings Per Share (EPS) forecast of -CH₣1.53 for the next financial year.
Find out moreWhat is the trend in the Molecular Partners AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Molecular Partners AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -40.5%.
As of the last closing price of CH₣3.47, shares in Molecular Partners AG were trading -25.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Molecular Partners AG PE Ratio?
The Molecular Partners AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣3.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Molecular Partners AG?
Molecular Partners AG's management team is headed by:
- William Burns - NEC
- Patrick Amstutz - CEO
- Andreas Emmenegger - CFO
- Michael Stumpp - COO
- Nicolas Leupin - MGB
- Gwendolyn Fyfe - NED
- Steven Holtzman - NED
- Sandip Kapadia - NED
- Vito Palombella - NED
- Michael Vasconcelles - NED